Maurice was pacing frantically across his trading desk, a half-peeled banana in one hand and FDA approval documents in the other, muttering about how the market gets it backwards.
There’s a peculiar moment in biotech investing when everything should be going up—approvals come through, clinical milestones hit, the regulatory gods smile upon you—and the stock goes down instead. It’s like discovering you’ve planted the perfect banana tree, watching it grow exactly as planned, and then the market punches it in the face. This is where we find ourselves with Rocket Pharmaceuticals (RCKT), and honestly, it’s exactly the kind of situation that gets me throwing bananas at my monitors.
Just last month, in late March 2026, Rocket secured FDA accelerated approval for KRESLADI—a gene therapy for severe LAD-I (Leukocyte Adhesion Deficiency-I) in children. This isn’t some vague Phase 2 whisper in a press release. This is a real, tangible regulatory win in one of the most brutal regulatory environments on Earth. And what happened? The stock tanked about 8.9%. That’s right. Good news got punched in the banana, and the market essentially said, “Thanks, but no thanks.”
This is why I’m interested. This is why Foxy flagged it. This is why we’re talking about it right now.
Let’s Talk About What’s Actually Happening Here
Rocket Pharmaceuticals is a late-stage biotech company focused on gene therapy for rare, devastating diseases. We’re not talking about common colds or lifestyle drugs. We’re talking about Danon disease, which destroys your heart. We’re talking about Fanconi Anemia, which mangles your bone marrow. We’re talking about rare genetic disorders where patients have limited options and even shorter timelines.
The company has two parallel pipelines: in vivo AAV (adeno-associated viral) programs and ex vivo lentiviral programs. Think of it like a banker with two branches—one focuses on treating you internally, the other involves removing cells, fixing them, and putting them back. Both approaches are sophisticated, both are challenging, and both can be extraordinarily valuable if they work.
Right now, Rocket has programs at various stages:
The cardiac gene therapy track (RP-A501 for Danon, RP-A601 for PKP2-ACM, RP-L301 for PKD) represents one of the most promising areas in the pipeline. Wedbush Securities recently called the company “significantly undervalued” as this cardiac therapy pipeline advances. That’s not casual commentary from a sleepy analyst—that’s a major investment bank essentially saying the market is pricing in failure when the science is pointing toward success.
The KRESLADI approval (RP-L201 for LAD-I) is the immediate catalyst. This is revenue-generating, patient-helping, validation-producing medicine. For a rare disease affecting children’s immune systems, this is genuinely life-changing. And the market’s response? A collective shrug followed by a downward pressure. Why? Because biotech markets are irrational, because people were maybe expecting a bigger pop, because profit-taking happens, because sometimes the market is just wrong.
The Banana Peel Economics
Here’s where I need to be honest with you: Rocket’s balance sheet is doing something weird, like a banana slowly browning on the counter. The debt-to-equity ratio is 8.97, which is high—Foxy mentioned it as “low debt” (I think Foxy meant to say it’s manageable given the biotech context), but it’s still meaningful leverage. The company is burning cash—free cash flow sits at negative $104 million annually. The market cap is only $393 million.
This is the nature of biotech. You’re burning cash to develop medicines. You don’t make profits until—if—you get approvals and can commercialize. Rocket already has one approval (KRESLADI), which means revenue is starting. They have potentially several more approvals in sight. The question isn’t whether they’ll ever have positive cash flow; it’s whether they’ll get there before the money runs out.
With a $393 million market cap and burning ~$105 million annually, they’ve theoretically got 3-4 years of runway if nothing changes. But something IS changing: KRESLADI is approved. RP-A501 (Danon) is in Phase 2. These aren’t hypothetical anymore. The money spent last year was burning through early-stage programs. Now it’s being spent on programs that are actively advancing toward market.
The beta is 0.574—nearly half the volatility of the broader market. This suggests that despite being a “risky” biotech company, the market perceives some stability in the program pipeline. It’s a small, paradoxical comfort. Like finding a banana that’s perfectly ripe, not overripe, not green—just right.
Why the Market Got It Wrong (For Now)
Biotech stock reactions to approvals can be categorized in roughly three ways: the company crushed expectations (stock goes up big), the company met expectations (stock flat or down slightly), or the company’s approval was priced in too early (stock goes down). Rocket seems to have experienced door number three.
In March 2026, gene therapy wasn’t a new concept anymore. The market had already seen approvals in this space. KRESLADI is significant, but it’s not revolutionary—it’s the expected next step for a company that had been telegraphing this approval for months or years. Institutions that bought on the Phase 1 or Phase 2 data took profits. Short-term traders who were betting on a bigger pop exited. And the stock drifted downward.
But here’s the thing: that’s exactly when smart money notices things. When a company gets approved and the stock goes down, you ask yourself: Is the market underestimating the commercial potential? Are they not seeing the pipeline? Are they focused too heavily on the balance sheet and not enough on the trajectory?
Wedbush’s recent call says yes to all of these. They’re saying the market is pricing in mediocrity when the science is screaming superiority. And I’m inclined to agree.
The Three-to-Five-Year Banana Split
Let’s think about the next few years. KRESLADI is generating revenue now—not huge revenue, because LAD-I is rare, but real revenue. RP-A501 (Danon disease) is in Phase 2. If the data is positive (and if Wedbush is right, it should be), an approval could come in 2027 or 2028. Danon disease is more common than LAD-I, so this has bigger commercial potential.
RP-L102 (Fanconi Anemia) is also in development. The more approvals Rocket gets, the more revenue streams they have, the faster they approach cash flow breakeven. And once they break even? Once they stop burning cash? The valuation picture changes entirely.
At $3.62 (near the recommendation entry of $3.48), Rocket is trading at a market cap of $393 million. Foxy’s target is $7.50, which would imply a market cap around $800 million—more than double. Is that reasonable? Let’s think about it through the lens of approved therapies and pipeline potential. If they have three approved therapies generating revenues, even small revenues, and three more in active development, a $800 million valuation isn’t wild. It’s not conservative, but it’s not fantasy either.
The short ratio is 4.64%, suggesting moderate short interest. Some bears are betting against this company. That’s normal for biotech, especially smaller caps. But it also means that if the science continues to validate, those shorts could become forced buyers, adding fuel to any upward move.
What Could Go Wrong (And Probably Should)
I have to say this plainly: this is a risky investment. Biotech always is. Here’s what keeps me up at night:
Cash runway. At negative $104 million in free cash flow, Rocket has maybe 3-4 years before needing to raise capital again. If they raise capital, it will dilute existing shareholders. That’s not a deal-breaker (it’s normal in biotech), but it’s real.
Commercialization risk. Just because KRESLADI is approved doesn’t mean it will be a commercial success. They have to manufacture it, distribute it, convince pediatricians to use it. Rare disease patients are easier to reach than common disease patients, but it’s still not trivial. The approval is proof of concept; commercial success is separate.
Clinical risk. The cardiac programs (Danon, PKP2, BAG3) are still in Phase 1 or Phase 2. Any of these could fail. If multiple programs fail, the thesis unravels. Gene therapy is powerful but unpredictable.
Competitive risk. Other biotech companies are also pursuing gene therapy in rare diseases. Rocket doesn’t have the space to itself. A competitor could leapfrog them with a better therapy or faster approval timeline.
These risks are real, and they’re built into the stock price. But they’re not certainties. They’re probabilities. And right now, the market seems to be pricing in higher probabilities of failure than the science suggests is warranted.
Why Foxy’s Call Makes Sense
Foxy flagged this as a “BUY” with high confidence (9 out of 10), targeting $7.50 from $3.48. That’s roughly a 2.15x return. Over what timeframe? Presumably 3-5 years, given the nature of biotech development. That’s not “get rich quick”—it’s “smart money recognizing value where others see risk.”
The reasoning is solid: late-stage biotech (check), gene therapy focus in high-value rare disease market (check), low debt-to-equity by biotech standards (check), conservative beta suggesting program stability (check), positioned for near-term clinical milestones (check), gene therapy sector seeing major approvals in 2025-2026 (check). And we’ve just seen one of those approvals happen. The thesis is playing out in real time.
The medium risk level is appropriate. This isn’t a “sure thing”—nothing in biotech is. But it’s not a lottery ticket either. It’s a calculated bet that the science is good, the management can execute, and the market will eventually value the company appropriately once another approval or two comes through.
The Monkey Momentum Index Verdict
I’m sitting here with half a banana in one hand, a calculator in the other, and honestly? I’m leaning into this. The market’s disappointment over the approval is creating an entry point that won’t last. Once the next positive data hits—and if Wedbush is right, it will—this stock will be re-rated upward. Investors who bought at $3.50 will look genius in two years when RCKT is trading at $6 or $7.
That doesn’t mean it’s a guarantee. That means it’s a bet worth making if you understand the science, accept the risks, and have a timeline measured in years, not months.
My monkey instincts are tingling. The FDA approval was validation. The market’s downward reaction was opportunity. Foxy’s call is well-reasoned. And Wedbush’s “significantly undervalued” comment is the kind of professional backing that makes me think we’re looking at mispricing, not misevaluation.
Bananas are for monkeys. Gene therapy is for humans. And discounted gene therapy companies are for patient investors.
Disclaimer: Trained Market Money, Maurice, and our entire primate analysis team provide entertaining market commentary only. While Maurice’s Monkey Momentum Index™ and banana-based technical analysis have shown mysterious accuracy, they should never be considered financial advice. All investment decisions should be made in consultation with qualified financial professionals, not monkeys – no matter how impressive their fruit-throwing abilities may be. For real financial advice, please consult your financial advisor, who probably doesn’t accept bananas as payment.
Coming next week: We’re peeling back the layers on a biotech company that’s doing something truly wild with CRISPR-based therapies. Maurice is already practicing his gene-editing analogies.
“In biotech, patience isn’t a virtue—it’s a prerequisite. But opportunity rewards those who wait.” — Maurice
Trained Market Monkey 